COVID-19 gives Akili’s digital ADHD treatment an early debut in US
Boston, US-based Akili, an affiliate of UK group PureTech Health, is still in the process of seeking FDA approval of the digital therapy as a prescription treatment. However, it has been able to offer it to children with ADHD and their families early because the FDA has relaxed regulations covering digital health devices for psychiatric conditions during the COVID-19 outbreak.
Other Articles in this Edition
Study Supports Using WURS and ASRS Jointly to Assess Adult ADHD
COVID-19 gives Akili’s digital ADHD treatment an early debut in US
ADHD and Emotions: What the DSM-5 Doesn’t Tell Us
ADHD breakthrough using artificial intelligence set to revolutionise diagnosis time
At-home schooling for children with ADHD: Creating a successful learning environment
Study finds early ADHD diagnosis risks ‘negative impact’
Aspergers or ADHD? The Answer Will Suprise You
I Never Suspected ADHD Could Be Linked to My Childhood Trauma